Effectiveness of Over-65 Pneumonia Jabs

It looks like pneumonia vaccinations for the over-65s are going to be scrapped in Great Britain as they have been proven to “not save lives.” The jabs that are meant to offer protection for a 10 year period, at a cost of approximately £20, but according to government-advisory body, the JCVI (Joint Committee on Vaccination and Immunization), it has had “no discernible impact” on lowering the number of pneumococcal disease. Simply put, it doesn’t offer the protection necessary for the older generation. Thus Professor David Salisbury (Government director of Immunization) has said the program should be stopped at least for the older generation. It is worth continuing it for children (but it is a slightly different vaccine anyway).

Other Problems with the Jab

Their job responsibilities include providing rehabilitative services to people with various emotional, mental, physical, or developmental impairments. cialis tablets 100mg You can pop over to this web-site purchase cialis online also order Kamagra online. There are plenty of even http://icks.org/n/data/ijks/1482460255_ij_file.pdf buy generic levitra cheaper anti ED medicines available on the internet and in shops. However one herbal method that has gain immense popularity in treating erectile dysfunction problem is herbal cheap cialis overnight.

It’s one thing if the vaccine is just not so effective, but it’s another thing if it becomes dangerous and that seems to be the case. In fact, the jab in “older people has been linked to 30 deaths and more than 3,300 reported side effects, including heart disorders and joint and muscle pain, according to official figures from the Medicines and Healthcare products Regulatory Agency.” So why is this happening? In theory, the vaccine should be preventing “23 common types of pneumococcal disease bugs.” But somehow it’s not doing the trick, at least in the over-65 age group. There has also been criticism that this scenario wasn’t revealed earlier. As Charlotte Linacre from the TaxPayers’ Alliance commented, “the Department of Health shouldn’t just throw money at a project without reviewing its effectiveness.” While this is all very well and good however, there is bound to be criticism and questions about how to help the over-65s in this regard. True, it may not work, but for sure this group is particularly vulnerable to this disease and need some kind of protection. Maybe this topic will be explored, and hopefully in the not-too-distant future.